sk&f 86002 has been researched along with Acquired Immunodeficiency Syndrome in 1 studies
6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole: inhibits p38 MAP kinase
Acquired Immunodeficiency Syndrome: An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bender Ignacio, RA | 1 |
| Lee, JY | 1 |
| Rudek, MA | 1 |
| Dittmer, DP | 1 |
| Ambinder, RF | 1 |
| Krown, SE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Trial of PTC299 in Patients With HIV-Related Kaposi's Sarcoma[NCT00686842] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2008-09-30 | Terminated (stopped due to Drug supply unavailable.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patients who experienced an adverse event of grade 3 or greater (NCT00686842)
Timeframe: All study visits
| Intervention | participants (Number) |
|---|---|
| VEGF Inhibitor PTC299 | 7 |
1 trial available for sk&f 86002 and Acquired Immunodeficiency Syndrome
| Article | Year |
|---|---|
Brief Report: A Phase 1b/Pharmacokinetic Trial of PTC299, a Novel PostTranscriptional VEGF Inhibitor, for AIDS-Related Kaposi's Sarcoma: AIDS Malignancy Consortium Trial 059.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; DNA, Viral; Enzyme | 2016 |